Key Highlights

  • Lumexa Imaging shares are trading down 3.63% at $15.37 versus a prior close of $15.95.
  • The stock jumped 14.58% on Wednesday after third quarter results.
  • Revenue rose 5% to $272 million, and adjusted EPS was $0.26.
  • 2026 adjusted EPS guidance was raised to $0.86 to $0.90 from $0.71 to $0.77.
  • Net Leverage fell to 3.5 times from 5.6 times a year ago.

Lumexa Imaging (NASDAQ:LMRI) is trading down 3.63% at $15.37, giving back part of Wednesday's 14.58% jump to $15.95. Third quarter adjusted Earnings of $0.26 per share beat the roughly $0.18 analysts expected, and the outpatient imaging provider raised its full-year earnings outlook.

Quarter Results

Revenue rose 5% to $272 million, with system-wide outpatient Revenue up 7.7% and Volume up 4.9%, the strongest of 2026. Advanced modality mix reached a record. Adjusted EBITDA was $62.6 million, a 23.0% margin. GAAP earnings were $0.07 per share, and Net Income was $7.2 million versus a $3.5 million loss a year ago.

Balance Sheet Progress

Free Cash Flow was $20.6 million, and cash stood at $90 million. Net leverage fell to 3.5 times from 5.6 times a year earlier, a major step for a company that recently went public.

Guidance Details

Adjusted EBITDA guidance was narrowed to $236 million to $240 million, with the $238 million midpoint unchanged. Revenue guidance of $1.045 billion to $1.097 billion was reiterated. Adjusted EPS guidance rose to $0.86 to $0.90 from $0.71 to $0.77, mainly because of a lower tax rate rather than stronger operations. Free cash flow conversion is expected at 30% or more of adjusted EBITDA.

Policy and Expansion

A final site-neutral payment rule expands the addressable market to about $77 billion by moving more imaging into lower-cost outpatient settings. Lumexa also added a joint venture with Advocate Health in Illinois, bringing its total to 10. Raymond James holds a $19 target with a Strong Buy rating.

Operations, Not Tax, Decide the Next Move

After a 14.58% jump, today's pullback reflects questions over how much of the raise is tax-driven. With the EBITDA midpoint unchanged, investors will watch whether volume growth near 5% holds, whether advanced modality mix keeps rising and whether new joint ventures add to revenue.

Fourth quarter volume and leverage below 3.5 times are the next markers.